Chagas heart disease is an inflammatory cardiomyopathy that develops in approximately
one-third of people infected with the protozoan parasite Trypanosoma cruzi. One way T …

Trypanosoma cruzi interacts with the different arms of the innate and adaptive host's immune
response in a very complex and flowery manner. The history of host-parasite co-evolution …

Despite medical progress, more than a billion people still suffer daily from parasitic
infections. Vaccination is recognized as one of the most sustainable options to control …

Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a
critical lack of methods for prevention of infection or treatment of acute infection and chronic …

Chagas disease (ChD), caused by the hemoflagellate parasite Trypanosoma cruzi, affects
six to seven million people in Latin America. Lately, it has become an emerging public …

Trypanosoma cruzi infection causes Chagas disease, which affects 7 million people
worldwide. Two drugs are available to treat it: benznidazole and nifurtimox. Although both …

In this study, we evaluated the long-term efficacy of a two-component subunit vaccine
against Trypanosoma cruzi infection. C57BL/6 mice were immunized with TcG2/TcG4 …

The development of suitable safe adjuvants to enhance appropriate antigen-driven immune
responses remains a challenge. Here we describe the adjuvant properties of a small …

Chagas disease, caused by the parasite Trypanosoma cruzi, is considered endemic in more
than 20 countries but lacks both an approved vaccine and limited treatment for its chronic …

Trypanosoma cruzi is a protozoan parasite that causes Chagas disease. Globally 6 to 7
million people are infected by this parasite of which 20–30% will progress to develop …